SCHEMBL9944254

SCHEMBL9944254

CC(=O)c1ccc(NC(=O)c2cc(C)c(OC(C)C)c(OC(C)C)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.51
RAB9A P51151 4/20 0.51
NPC1 O15118 3/20 0.51
MAPT P10636 6/20 0.50
ALDH1A1 P00352 4/20 0.50
MAPK1 P28482 2/20 0.50
TOP1 P11387 1/20 0.50
PLAU P00749 2/20 0.46
KMT2A Q03164 3/20 0.45
POLB P06746 1/20 0.45
TP53 P04637 3/20 0.44
ABCB1 P08183 1/20 0.44
LMNA P02545 3/20 0.43
MCL1 Q07820 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ABCG2 Q9UNQ0 1/20 0.43
PTGER4 P35408 1/20 0.43
MEN1 O00255 1/20 0.42
GFER P55789 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9944124 0.90 MAPT (0.50) SMN1; SMN2RAB9ANPC1MAPTALDH1A1
SCHEMBL9944197 0.86 TAS1R3 (0.52) SMN1; SMN2RAB9ANPC1MAPTALDH1A1
SCHEMBL9944179 0.86 TAS1R3 (0.52) SMN1; SMN2RAB9ANPC1MAPTTOP1
SCHEMBL9944247 0.85 RAB9A (0.55) SMN1; SMN2RAB9ANPC1MAPTALDH1A1
SCHEMBL9944248 0.83 RORC (0.51) SMN1; SMN2RAB9ANPC1MAPTALDH1A1
SCHEMBL9944253 0.83 MAPT (0.50) SMN1; SMN2RAB9ANPC1MAPTALDH1A1
SCHEMBL9944212 0.81 TAS1R3 (0.60) SMN1; SMN2RAB9AMAPTALDH1A1MAPK1
SCHEMBL1458073 0.81 PKM (0.53) SMN1; SMN2RAB9ANPC1MAPTALDH1A1
SCHEMBL9944177 0.80 TAS1R3 (0.57) SMN1; SMN2RAB9ANPC1MAPTALDH1A1
SCHEMBL9944193 0.80 RORC (0.49) SMN1; SMN2RAB9ANPC1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG SMN1; SMN2 696/4885RAB9A 271/4885NPC1 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.